Cellectar Biosciences Inc.
Organization details
- Legal name
- Cellectar Biosciences Inc.
- Former names
- Novelos Therapeutics, INC. Common Horizons Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Florham Park
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CLRB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001279704
- EIN
- 04-3321804
Board of directors
-
Andrew Gu · DirectorSince 2026
-
Asher Chanan-Khan · DirectorSince 2023
-
Douglas J. Swirsky · DirectorSince 2023
-
Frederick W. Driscoll · DirectorSince 2023
-
James Caruso V · Director · President & CEOSince 2023
-
John Neis · DirectorSince 2023
-
Stefan Loren · DirectorSince 2023
Chief executives
Director election results
Annual meeting of July 7, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.5%
-
98.8%
Board connections
1 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
Cue Biopharma Inc. Same sectorvia Frederick W. Driscoll
-
Lite Strategy Inc. Same sectorvia Frederick W. Driscoll
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $49,997
- 2 purchases by 2 insiders
- Sold, last 12 months
- $733
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 7, 2026 | Longcor Jarrod Officer (Chief Operating Officer) | Open-market purchase | +8,680 | $2.88 | $24,998 |
| May 7, 2026 | James Caruso V Director, Officer (Chief Executive Officer) | Open-market purchase | +8,680 | $2.88 | $24,998 |
| Dec 12, 2025 | John Neis Director | Open-market sale | −198 | $3.70 | $733 |
| Jul 2, 2025 | James Caruso V Director, Officer (Chief Executive Officer) | Open-market purchase | +10,000 | $4.99 | $49,900 |
| Jul 2, 2025 | Longcor Jarrod Officer (Chief Operating Officer) | Open-market purchase | +10,000 | $4.99 | $49,900 |
| Jul 2, 2025 | Kolean Chad J Officer (Chief Financial Officer) | Open-market purchase | +5,000 | $4.99 | $24,950 |
| Jan 10, 2025 | Longcor Jarrod Officer (Chief Operating Officer) | Open-market purchase | +30,000 | $0.28 | $8,400 |
| Dec 8, 2023 | Lea Darrell Shane Officer (Chief Commercial Officer) | Grant or award | +39,599 | — | — |
| Dec 8, 2023 | Kolean Chad J Officer (Chief Financial Officer) | Grant or award | +42,554 | — | — |
| Dec 8, 2023 | Shustov Andrei Officer (Senior Vice President, Medical) | Grant or award | +47,856 | — | — |
| Dec 8, 2023 | Longcor Jarrod Officer (Chief Operating Officer) | Grant or award | +42,927 | — | — |
| Dec 8, 2023 | James Caruso V Director, Officer (President and CEO) | Grant or award | +40,596 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Cellectar Biosciences Inc.
Who is the CEO of Cellectar Biosciences Inc.?
James Caruso V is Cellectar Biosciences Inc.'s President and CEO.
How many directors are on Cellectar Biosciences Inc.'s board?
Cellectar Biosciences Inc.'s board has 7 directors: Andrew Gu, Asher Chanan-Khan, Douglas J. Swirsky, Frederick W. Driscoll, James Caruso V, John Neis and Stefan Loren.
Are Cellectar Biosciences Inc. insiders buying or selling shares?
Over the last 12 months, Cellectar Biosciences Inc. insiders bought $49,997 of shares in 2 purchases and sold $733 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="cellectar-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.